First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.
Saved in:
| Title: | First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors. |
|---|---|
| Authors: | Powderly JD 2nd; Carolina BioOncology Institute, Huntersville, NC 28078, United States., Gutierrez ME; Hackensack University Medical Center, Hackensack, NJ 07601, United States., Balmanoukian AS; The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA 90025, United States., Hoyle PE; Incyte Corporation, Wilmington, DE 19803, United States., Dong Z; Incyte Corporation, Wilmington, DE 19803, United States., Cheng L; Incyte Corporation, Wilmington, DE 19803, United States., Chen X; Incyte Corporation, Wilmington, DE 19803, United States., Janik JE; Incyte Corporation, Wilmington, DE 19803, United States., Bourayou N; Incyte Biosciences International Sàrl, 1110 Morges, Switzerland., Hamid O; The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA 90025, United States. |
| Source: | The oncologist [Oncologist] 2025 Jul 04; Vol. 30 (7). |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyaf136 |
